Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.64 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.58 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salcaprozic Acid SCHEMBL30668801 | 1.00 | NAAA (0.68) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL14088978 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL6383063 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL29385752 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL2331916 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL14088979 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL4586235 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL664024 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| SCHEMBL13593340 | 0.98 | NAAA (0.70) | NAAAALDH1A1HTTNPC1MAPT | |
| Salcaprozic Acid SCHEMBL2159928 | 0.97 | NAAA (0.68) | NAAAALDH1A1HTTNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2019-11-07 | — | — | US | claimed |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20240000879-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | SPOKE SCIENCES, INC. (US) | 2024-01-04 | — | — | US | disclosed |
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230075677-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2023-03-09 | — | — | US | disclosed |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | RECEPTOR HOLDINGS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| WO-2022072864-A2 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | RECEPTOR HOLDINGS, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | RECEPTOR HOLDINGS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3928776-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | Receptor Holdings, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | RECEPTOR HOLDINGS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-2538945-A2 | ORAL B12 THERAPY | Emisphere Technologies, Inc. (US) | 2013-01-02 | — | — | EP | disclosed |
| US-8288360-B2 | Method of treating vitamin B12 deficiency | EMISPHERE TECHNOLOGIES, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2011156563-A2 | ORAL IRON DEFICIENCY THERAPY | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| US-20110293589-A1 | METHOD OF TREATING VITAMIN B12 DEFICIENCY | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8022048-B2 | Method of treating vitamin B12 deficiency | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| WO-2011106378-A2 | ORAL B12 THERAPY | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20110207693-A1 | Oral B12 Therapy | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2215047-A1 | METHOD OF TREATING VITAMIN B12 DEFICIENCY | Emisphere Technologies, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100016255-A1 | METHOD OF TREATING VITAMIN B12 DEFICIENCY | EMISPHERE TECHNOLOGIES INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009059188-A1 | METHOD OF TREATING VITAMIN B12 DEFICIENCY | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230075677-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | NAAA 152/4885ALDH1A1 3578/4885HTT 1152/4885 |
| US-20230293479-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | NAAA 76/4885ALDH1A1 3427/4885HTT 949/4885 |
| US-11246852-B2 | Fast-acting plant-based medicinal compounds and nutritional supplements | SLC1A5, SLC43A1, SLC27A2 | NAAA 152/4885ALDH1A1 3578/4885HTT 1152/4885 |
| US-20190336472-A1 | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | GPR18, SLC1A5, CNR2 | NAAA 76/4885ALDH1A1 3427/4885HTT 949/4885 |
| US-20240000879-A1 | HERBAL COMPOSITIONS WITH IMPROVED BIOAVAILABILITY | SLC7A1, SLC1A5, SLC3A2 | NAAA 444/4885ALDH1A1 1771/4885HTT 2267/4885 |
| US-20240009208-A1 | STABILIZATION OF CANNABINOIDS WITHIN SOLID DOSAGE FORMS | DGKZ, DSP, DMPK | NAAA 2360/4885ALDH1A1 4844/4885HTT 3798/4885 |
| US-20110293589-A1 | METHOD OF TREATING VITAMIN B12 DEFICIENCY | HMBS, HBB, MMAB | NAAA 1924/4885ALDH1A1 3694/4885HTT 3404/4885 |
| US-20110207693-A1 | Oral B12 Therapy | MMAB, SLC19A1, HMBS | NAAA 1869/4885ALDH1A1 3585/4885HTT 663/4885 |
| US-20100016255-A1 | METHOD OF TREATING VITAMIN B12 DEFICIENCY | HMBS, HBB, MMAB | NAAA 1924/4885ALDH1A1 3694/4885HTT 3404/4885 |
| US-20210393575-A1 | N-ACYLATED FATTY AMINO ACIDS TO REDUCE ABSORPTION VARIABILITY IN CANNABINOID BASED COMPOSITIONS | FAAH, CNR2, FABP2 | NAAA 39/4885ALDH1A1 3661/4885HTT 1270/4885 |
| US-20220133685-A1 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS | SLC1A5, SLC43A1, SLC27A2 | NAAA 152/4885ALDH1A1 3578/4885HTT 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.